Inotuzumab ozogamicin, a calicheamicin-conjugated a monoclonal antibody binding to CD22-expressing tumor cells, can be internalized and release cytotoxic calicheamicin inside the cell, leading to DNA damage and the following cell death.383 Inotuzumab ozogamicin was approved for the treatment of adults with refractory or relapsed leukemia. This evidence concerns the gene CD22 and leukemia.